Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model

Current Medical Research and Opinion

Volumn 20, Issue 8, 2004, Pages 1227-1233

  Lanier, Bobby Q ^a,j   Finegold, Ira ^b   D'Arienzo, Peter ^c,d   Granet, David ^e,f   Epsteins, Arthur B ^g,h   Ledgerwood, Greg L ⁱ  

^a Fort Worth Allergy Asthma Association   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c ST VINCENT S HOSPITAL   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

^e A F R Dept Pediat Ophthalmol

^f UNIVERSITY OF CALIFORNIA   (United States)

^g NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^h North Shore Contact Lens & Vision Consultants PC   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j North Texas Institute for Clinical Trials   (United States)

more..

Author keywords

Conjunctival allergen challenge model; Epinastine; Olopatadine; Seasonal allergic conjunctivitis treatment

Indexed keywords

ALLERGEN; EPINASTINE; EYE DROPS; OLOPATADINE; PLACEBO;

ADULT; ALLERGIC CONJUNCTIVITIS; ARTICLE; CHEMOSIS; CLINICAL TRIAL; CONJUNCTIVAL ALLERGEN CHALLENGE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG INSTILLATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OCULAR PRURITUS; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 4344632128     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904125004330     Document Type: Article

References (33)

1. Weeks ER. Epidemiology of hay fever and perennial allergic rhinitis. Monogr Allergy 1987;21:1-20
2. Abelson MB, George MA, Garafalo C. Differential diagnosis of ocular disorders. Ann Allergy 1993;70:95-113
3. Abelson MB, Smith L, Chapin M. Ocular allergic disease: mechanisms, disease sub-types, treatment. The Ocular Surface 2003;1(3):127-49
4. Abelson MB, Pyun J. In: Abelson MB, editor. Allergic diseases of the eye. Philadelphia: W.B. Saunders; 2000. p. 50-68
5. 2-receptors in the human ocular surface. Arch Ophthalmol 1981;99:302-4
6. Woodward DF, Legard SE, Nieves AL. Conjunctival immediate hypersensitivity: re-evaluation of histamine involvement in the vasopermeability response. Invest Ophthalmol Vis Sci 1986;27:57-63
7. New drugs for allergic conjunctivitis. Med Lett Drugs Ther 2000;42:39-40
8. Aguilar AJ. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate. Acta Ophthalmol Scand 2000;78:52-5
9. Sharif NA, Xu SX, Miller ST, et al. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases. J Pharmacol Exp Ther 1996;278:1252-61
10. Yanni JM, Stephens DJ, Miller ST, et al. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/ antihistaminic agent. J Ocul Pharmacol Ther 1996;12:389-400
11. Yanni JM, Sharif NA, Gamache DA, Miller ST, Weimer LK, Spellman JM. A current appreciation of sites for pharmacological intervention in allergic conjunctivitis; effects of new topical ocular drugs. Acta Ophthalmol Scand 1999;77:33-7
12. Ohmori K, Hayashi K, Kaise T, et al. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J Pharmacol 2002;88(4):379-97
13. Leonardi, A, Abelson, MB. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans. Clin Ther 2003;25:2539-52
14. Berdy GJ, Spangler DL, Bensch G, Berdy SS, Brusatti RC. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.15% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model. Clin Ther 2000;22(7):826-33
15. Abelson MB. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. Ann Allergy Asthma Immunol 1998;81(3):211-8
16. Abelson MB, Spitalny L. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am J Ophthalmol 1998;125:797-804
17. PATANOL® Product Insert. Alcon Laboratories, Ft. Worth, Texas. 2004
18. Katelaris CH, Ciprandi G, Missotten L, Turner FD, Bertin D, Berdeaux G; International Olopatadine Study Group. A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis. Clin Ther 2002;24(10):1561-75
19. Butrus S, Greiner JV, Discepola M, Finegold I. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model. Clin Ther 2000;22:1462-72
20. Abelson MB, Welch DL. An evaluation of onset and duration of action of Patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model. Acta Ophthalmol Scand Suppl 2000;230:60-3
21. Abelson MB, Turner D. A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis. Clin Ther 2003;25(3):931-47
22. Yanni JM, Weimer LK, Sharif NA, et al. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Arch Ophthalmol 1999;117:643-7
23. Tasaka K. Epinastine: an update of its pharmacology, metabolism, clinical efficacy and tolerability in the treatment of allergic diseases. Drugs Today 2000;36:735-57
24. ELESTAT® Package insert. Allergan, Inc., Irvine, California. 2003
25. Abelson MB, Gomes PJ, Crampton HJ, Schiffman RM, Bradford RR, Whitcup SM. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. Clin Ther 2004;26(1):35-47
26. Deschenes J, Discepola M, Abelson MB. Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model. Acta Ophthalmol Scand 1999;(Suppl)77:47-52
27. Spangler DL, Bensch G, Berdy GJ. Evaluation of the efficacy of olopatadine hydrochoride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. Clin Ther 2001;23(8): 1272-80
28. Berdy GJ, Stoppel JO, Epstein AB. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model. Clin Ther 2002;24(6):918-29
29. Lanier BQ, Abelson MB, Berger WE, et al. Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propinate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge. Clini Ther 2002;24(7):1161-74
30. Abelson MB, Chambers WA, Smith LM. Conjunctival allergen challenge: a clinical approach to studying allergic conjunctivitis. Arch Ophthalmol 1990;108(1):84-8
31. Abelson, MB. Comparison of the conjunctival allergen challenge model with the environmental model of allergic conjunctivitis. Acta Ophthalmol Scand 1999;228:38-42
32. Whitcup SM, Bradford R, Lue J, Schiffman RM, Abelson MB. Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis. Clin Ther 2004;26(1):29-34
33. Brockman HL, Momsen MM, Knudtson JR, Miller ST, Graff G, Yanni JM. Interactions of olopatadine and selected antihistamines with model and natural membranes. Ocular Immun Inflamm 2003;11:247-68